The Producer of an Innovative Wearable Insulin Pump
EOFlow, a Korean pharmaceutical company that has developed an innovative wearable insulin pump, plans to expand its wearable drug delivery solutions to other non-insulin drugs.
The company disclosed this plan during a session at the 2021 spring symposium of the Korean Endocrine Society, which was held at the Yeosu EXPO Convention Center from April 9-10.
At the symposium, themed “Endocrinology Meets Immunology,” medical experts in the field of endocrinology shared their opinions on recent trends.
Jesse Kim, the founding CEO of EOFlow, presented a session on “Wearable Diabetes Management: Today and Tomorrow,” focusing on wearable insulin pumps and artificial pancreas.
Kim discussed an ongoing digital and point-of-care (POC) trend in the healthcare industry, introducing EOFlow’s platform technology. Digital healthcare is emerging as a new mainstream in healthcare service due to financial burden on medical expenses, ICT technology advancement, and a paradigm shift in medicine. Kim emphasized that EOFlow would develop a virtuous cycle of POC and digital trend based on its platform technology.
EOFlow has recently launched wearable insulin pump “EOPatch” in Korea. EOPatch is a disposable wearable insulin pump which is used to continuously deliver insulin in blood glucose control. It is the world’s second commercially available wearable disposable insulin pump. It provides advanced features to improve insulin users’ quality of life. It is wireless/tubeless, small and light, and waterproof. It offers a long wear time (3.5 days) to allow twice-a-week compliance, and a faster needle insertion than other wearable solutions for reduced insertion pain.
Kim said that with an artificial pancreas, monitoring users’ blood glucose level and automatically adjusting insulin delivery for controlling blood glucose levels would be possible. EOFlow plans to conduct a feasibility clinical study next month with “EOPatch X,” a closed-loop, two-part wearable artificial pancreas solution. EOFlow also has an integrated wearable artificial pancreas solution, “EOPancreas,” in its future product portfolio.
“EOFlow plans to expand its wearable drug delivery solutions to other non-insulin drugs. As a wider range of subcutaneous drugs become available, connected, digital wearable drug delivery solutions such as EOFlow’s are gaining increasing attention,” a company official said. “EOFlow will enhance its competitiveness in the global medical device and pharmaceutical industry.”
EOFlow showcased its wearable insulin pump EOPatch at the symposium. Its exhibition booth was accompanied by Huons, an exclusive distributor of EOPatch in the Korean market.